Abstract
Objective To observe the efficacy of intravitreal Ranibizumab(IVR) for the treatment in aggressive posterior retinopathy of prematurity(AP-ROP). Methods The data of 44 eyes of 22 premature infants with AP-ROP were reviewed and analyzed. All the infants received IVR(10 mg/ml, 0.025ml)as the initial treatment within 24 hours after diagnosis. Anterior segment examinations were performed 1 and 2 days after injection, and fundus examination were performed 3, 7, 14 and 30 days after treatment. Follow-up time was 8 - 24 weeks with average (15.80±7.31) weeks. If the infants didn’t respond positively to the treatment, they were repeated IVR or received laser photocoagulation treatment once more. Results After IVR injections, AP-ROP regression exhibited in 28 eyes(63.64%). The disease was progressive in 16 eyes (36.36%). Avascular areas were still visible in fundus Ⅲ areas in 4 eyes among 28 eyes.No systemic toxicity happened in cured children. Among 16 eyes, the disease was stable after laser photocoagulation in 10 eyes(22.73%); transfer to superior hospital in 4 eyes and 2 eyes gave up the treatment because of other diseases. Conclusion IVR is safe and effective for most AP-ROP infants.Some prematurity need combined with laser photocoagulation.Only few infants cannot be cured. A systemic toxicity could not be seen in cured children who accepted IVR. The side effects of few children’s eyes are shown in the peripheral blood vessels of the children. Key words: Retinopathy, prematurity, posterior, aggressive; Treatment; Ranibizumab, intravitreal
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Chinese Journal of Ocular Trauma and Occupational Eye Disease
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
